Correction to: Neuropsychopharmacology https://doi.org/10.1038/s41386-020-0663-6, published online 06 April 2020
Following the publication of this article, the authors have noticed that the definition of response in the legend of Fig. 2 of the original manuscript was incorrect. The corrected text is as follows:
Relationship between (2S,6S;2R,6R)-hydroxynorketamine (HNK) Cmax and antidepressant response to ketamine. The figure plots the difference in MADRS total score between ketamine and placebo arms (response; ketamine minus placebo) by (2S,6S;2R,6R)-HNK Cmax, at each timepoint. The slope for each relationship (with 95% confidence interval) is provided (see also Supplementary Table S2). Increased (2S,6S;2R,6R)-HNK maximum concentration was associated with less clinical response, but this relationship was most robust at later timepoints. MADRS Montgomery-Asberg Depression Rating Scale.
The scientific conclusions of this paper have not been affected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Farmer, C.A., Gilbert, J.R., Moaddel, R. et al. Correction: Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacol. 45, 1405 (2020). https://doi.org/10.1038/s41386-020-0699-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41386-020-0699-7
